Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $510.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 71.19% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Weiss Ratings lowered Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, April 6th. Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Needham & Company LLC lowered their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Jefferies Financial Group reiterated a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Finally, Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $471.96.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $297.92 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The stock has a market capitalization of $39.75 billion, a PE ratio of 81.40 and a beta of 0.31. The stock’s 50 day moving average price is $320.11 and its 200-day moving average price is $376.18. Alnylam Pharmaceuticals has a 52-week low of $245.96 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm earned ($0.44) EPS. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals will post 6.78 EPS for the current year.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 6,958 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $2,157,536.64. Following the transaction, the chief executive officer owned 85,662 shares in the company, valued at $26,562,072.96. This represents a 7.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 59,802 shares in the company, valued at $18,543,404.16. This trade represents a 3.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 38,656 shares of company stock valued at $12,370,696 in the last 90 days. Insiders own 0.86% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ALNY. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after buying an additional 268,313 shares in the last quarter. Capital Research Global Investors increased its stake in Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after acquiring an additional 31,184 shares during the last quarter. Groupama Asset Managment raised its holdings in shares of Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after acquiring an additional 151,480 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $895,816,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.